Stander S, Reboul C, Le S, Williams D, Chandler P, Costa M
Nat Commun. 2025; 16(1):2275.
PMID: 40055307
PMC: 11889217.
DOI: 10.1038/s41467-025-57492-4.
Jagomae T, Velling S, Tikva T, Maksimtsuk V, Gaur N, Reimets R
Diabetol Metab Syndr. 2025; 17(1):82.
PMID: 40050934
PMC: 11887366.
DOI: 10.1186/s13098-025-01651-6.
Hummel S, Kassl A, Arnolds S, Achenbach P, Berner R, Casteels K
Contemp Clin Trials Commun. 2025; 44:101434.
PMID: 39916680
PMC: 11799962.
DOI: 10.1016/j.conctc.2025.101434.
Mitsui E, Satomura A, Oikawa Y, Haisa A, Shimada A
Diabetol Int. 2025; 16(1):188-193.
PMID: 39877436
PMC: 11769921.
DOI: 10.1007/s13340-024-00776-9.
Lu J, Jiang C, Drabick J, Joshi M, Perimbeti S
Pharm Res. 2025; 42(1):25-47.
PMID: 39779619
PMC: 11785709.
DOI: 10.1007/s11095-024-03809-9.
Deaths Related to New-Onset Seizures After Vaccination.
Prahlow J
Acad Forensic Pathol. 2024; :19253621241297029.
PMID: 39600629
PMC: 11586932.
DOI: 10.1177/19253621241297029.
Evaluation of Biochemical Characteristics and Performance of the 3 Screen ICA ELISA Kit.
Kawasaki E, Takahashi Y, Komeda T, Sakuma M
Int J Mol Sci. 2024; 25(22).
PMID: 39596248
PMC: 11595002.
DOI: 10.3390/ijms252212182.
Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies.
ODonovan A, Gorelik S, Nally L
Front Endocrinol (Lausanne). 2024; 15:1477101.
PMID: 39568817
PMC: 11576206.
DOI: 10.3389/fendo.2024.1477101.
Antigen-specific T cell responses in autoimmune diabetes.
Dwyer A, Shaheen Z, Fife B
Front Immunol. 2024; 15:1440045.
PMID: 39211046
PMC: 11358097.
DOI: 10.3389/fimmu.2024.1440045.
Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases.
Hiwasa T, Yoshida Y, Kubota M, Li S, Zhang B, Matsutani T
Med Int (Lond). 2024; 4(5):45.
PMID: 38983794
PMC: 11228693.
DOI: 10.3892/mi.2024.169.
The Importance of Intra-Islet Communication in the Function and Plasticity of the Islets of Langerhans during Health and Diabetes.
Hill T, Hill D
Int J Mol Sci. 2024; 25(7).
PMID: 38612880
PMC: 11012451.
DOI: 10.3390/ijms25074070.
Improved Specificity of Glutamate Decarboxylase 65 Autoantibody Measurement Using Luciferase-Based Immunoprecipitation System Assays.
Wyatt R, Grace S, Brigatti C, Marzinotto I, Gillard B, Shoemark D
Diabetes. 2024; 73(4):565-571.
PMID: 38232306
PMC: 10958581.
DOI: 10.2337/db23-0550.
Pathophysiological Effects of Autoantibodies in Autoimmune Encephalitides.
Ryding M, Mikkelsen A, Nissen M, Nilsson A, Blaabjerg M
Cells. 2024; 13(1).
PMID: 38201219
PMC: 10778077.
DOI: 10.3390/cells13010015.
Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets.
Chen B, Yu P, Chan W, Xie F, Zhang Y, Liang L
Signal Transduct Target Ther. 2024; 9(1):6.
PMID: 38169461
PMC: 10761908.
DOI: 10.1038/s41392-023-01679-y.
Relationship between β-Cell Autoantibodies and Their Combination with Anthropometric and Metabolic Components and Microvascular Complications in Latent Autoimmune Diabetes in Adults.
Bulum T, Vucic Lovrencic M, Knezevic Cuca J, Tomic M, Vuckovic-Rebrina S, Duvnjak L
Biomedicines. 2023; 11(9).
PMID: 37761002
PMC: 10526032.
DOI: 10.3390/biomedicines11092561.
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.
Sacks D, Arnold M, Bakris G, Bruns D, Horvath A, Lernmark A
Diabetes Care. 2023; 46(10):e151-e199.
PMID: 37471273
PMC: 10516260.
DOI: 10.2337/dci23-0036.
Anti-Islet Autoantibodies in Type 1 Diabetes.
Kawasaki E
Int J Mol Sci. 2023; 24(12).
PMID: 37373160
PMC: 10298549.
DOI: 10.3390/ijms241210012.
Anti-GAD65 autoantibody levels measured by ELISA and alternative types of immunoassays in relation to neuropsychiatric diseases versus diabetes mellitus type 1.
Zong S, Vinke A, Du P, Hoffmann C, Mane-Damas M, Molenaar P
Front Neurol. 2023; 14:1111063.
PMID: 37305746
PMC: 10248002.
DOI: 10.3389/fneur.2023.1111063.
The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness.
Fyvie M, Gillespie K
Front Immunol. 2023; 14:1158278.
PMID: 37256143
PMC: 10225507.
DOI: 10.3389/fimmu.2023.1158278.
Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes.
Takehana N, Fukui T, Mori Y, Hiromura M, Terasaki M, Ohara M
J Diabetes Investig. 2023; 14(7):856-863.
PMID: 37082800
PMC: 10286791.
DOI: 10.1111/jdi.14016.